Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Platinum-based Chemotherapy in SMARCA4-Deficient Lung Cancer
NCT07307443Phase 2Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC). Primary endpoint: Progression-Free Survival at 2 years. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07307443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307443.